EUVIMEDObjevte EUVIMED
Crossref

Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN ‐ IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD)

Hardik Rughwani iD, Rupa Banerjee iD, Rajendra Patel, Harshini Reddy, D Nageshwar Reddy iD

Alimentary Pharmacology & Therapeutics · 2026-11-13

DOI: 10.1111/apt.71091 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2026-11-13. Written by Hardik Rughwani and 4 co-authors. Institution: Department of Medical Gastroenterology, Asian Institute of Gastroenterology (AIG Hospitals), Hyderabad, India. 52 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Healthcare contributes 4.4%–5% of global greenhouse gas emissions. Inflammatory bowel disease (IBD) requires repeated diagnostic investigations throughout a patient's lifetime, adding to healthcare's environmental footprint. However, the carbon footprint and cost of IBD diagnostic modalities have not been systematically compared Aims To quantify per‐procedure emissions and relative costs of IBD diagnostics and model potential savings from intestinal ultrasound (IUS) when clinically appropriate.

Methods

This prospective observational study quantified operational emissions at AIG Hospitals, Hyderabad, India, during December 2025 using the Greenhouse Gas Protocol, institutional data, and a three‐state power model. Procedures included laboratory tests (27,330), colonoscopy/enteroscopy (1290), CT (1520), MRI (589), and IUS (923). Sensitivity analyses were performed to assess the robustness of emission estimates by varying assumptions regarding infrastructure allocation, equipment power consumption, procedure volumes, and electricity grid emission factors.

Results

Emissions ranged from 0.462 kg CO 2 e per laboratory test to 21.25 kg CO 2 e per MRI. IUS (0.850 kg CO 2 e) was the lowest‐carbon imaging modality, with 4.6‐, 6.8‐, and 25.0‐fold lower emissions than colonoscopy/enteroscopy, CT, and MRI, respectively. Cross‐sectional imaging contributed 53.7% of total emissions (39,778 kg CO 2 e), versus 2.0% for IUS. Costs increased with emissions. When clinically appropriate, substituting IUS for colonoscopy or MR enterography could reduce per‐procedure emissions by 78.0% and 96.0%, respectively.

Conclusions

Carbon emissions and cost rise together across IBD diagnostics; when clinically appropriate, IUS is the lowest‐carbon, lowest‐cost imaging modality. Patient‐level studies are needed to confirm modelled savings. Trial Registration ClinicalTrials.gov NCT07431983

Subjects

Author keywords

carbon footprintgreen endoscopyinflammatory bowel diseaseintestinal ultrasoundsustainable healthcare

Authors and institutions

  • Department of Medical Gastroenterology, Asian Institute of Gastroenterology (AIG Hospitals), Hyderabad, India.
  • Department of Radiology, Asian Institute of Gastroenterology (AIG Hospitals), Hyderabad, India.

ORCID profiles: Hardik Rughwani, Rupa Banerjee, D Nageshwar Reddy

Cite

APA

Rughwani, H., Banerjee, R., Patel, R., Reddy, H., & Reddy, D. N. (2026). Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN ‐ IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD). Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71091

Vancouver

Rughwani H, Banerjee R, Patel R, Reddy H, Reddy DN. Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN ‐ IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD). Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71091

BibTeX
@article{Rughwani2026,
  author = {Rughwani, Hardik and Banerjee, Rupa and Patel, Rajendra and Reddy, Harshini and Reddy, D Nageshwar},
  title = {Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN ‐ IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD)},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.71091}
}
Start for free →